Stryker Corporation (SYK)
Stryker: Strong Growth, But Valuation Is A Concern
Stryker (SYK) delivered strong Q3 2025 results, raising full-year guidance on robust organic growth across both MedSurg & Neurotechnology and Orthopaedics segments. SYK achieved double-digit organic sales and EPS growth, supported by margin expansion and successful product launches. Despite operational strength, SYK trades at a significant valuation premium to sector peers, with a PEG ratio above 2 and earnings growth in line with the S&P 500.
All You Need to Know About Stryker (SYK) Rating Upgrade to Buy
Stryker (SYK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stryker: Striking Again
Stryker continues to deliver strong organic growth, having posted organic growth rates of around 10% for a long period of time now. The $4.9 billion Inari Medical acquisition announced this year will boost the neurovascular business and slightly increase leverage, but deleveraging attempts are quite impressive. Valuation multiples have compressed to 26x earnings, making SYK more appealing as earnings outpace share price gains and leverage ratios come down.
Compared to Estimates, Stryker (SYK) Q3 Earnings: A Look at Key Metrics
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Stryker Corporation (SYK) Q3 2025 Earnings Call Transcript
Stryker Corporation ( SYK ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Kevin Lobo - Chairman, CEO & President Jason Beach - Vice President of Finance & Investor Relations Preston Wells - VP & CFO Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Travis Steed - BofA Securities, Research Division Samantha Munoz Nicholas Amicucci - Evercore ISI Institutional Equities, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Jennifer Reena Rabinowitz - Goldman Sachs Group, Inc., Research Division Pito Chickering - Deutsche Bank AG, Research Division Joanne Wuensch - Citigroup Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Kendall Au - RBC Capital Markets, Research Division Presentation Operator Welcome to the Third Quarter 2025 Stryker Earnings Call. My name is Robbie, and I'll be your operator for today's call.
Stryker (SYK) Q3 Earnings and Revenues Beat Estimates
Stryker (SYK) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $2.87 per share a year ago.
Stryker Lifts Full-Year Sales View After Third-Quarter Revenue Rises
The medical products maker now expects sales to grow 9.8% to 10.2% in the full year.
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.
Stryker's Robotics and Global Gains Offset by Macro Concerns
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.
Stryker Q2: Record Mako Installation And High Utilization
I reiterate a Hold rating on Stryker Corporation, with a fair value of $382 per share, despite recent strong quarterly results. Stryker's Mako installations and utilization remain robust, and upcoming Mako Spine and shoulder launches are on track to drive future growth. SYK management is focused on margin expansion through supply chain efficiencies, but cost synergies from past acquisitions remain under-realized.
Stryker: Strong Multi-Faceted Growth Continuing To Support The Shares
Stryker continues to outperform peers with strong revenue growth, margin expansion, and successful product innovation. Recent quarterly results beat expectations, driven by robust performance across the business and ongoing market share gains. Management remains focused on growth and margin optimization, with M&A and innovation — especially in robotics and neuromodulation — central to the strategy.
Stryker (SYK) Upgraded to Buy: What Does It Mean for the Stock?
Stryker (SYK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
